Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event
Mol Clin Oncol. 2022 Jun 1;17(1):120. doi: 10.3892/mco.2022.2553. eCollection 2022 Jul.ABSTRACTAseptic meningitis is a rare immune-related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non-specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non-small cell lung cancer (NSCLC). The present study includes a report of such a case and a review of the related literature. A 67-year-old Japanese man received first-line pembrolizumab treatment for ...
Source: Clinical Lung Cancer - June 24, 2022 Category: Cancer & Oncology Authors: Genki Inui Yoshihiro Funaki Haruhiko Makino Hirokazu Touge Katsunori Arai Keisuke Kuroda Yuuki Hirayama Ryohei Kato Takafumi Nonaka Kohei Yamane Yasuhiko Teruya Yuriko Sueda Tomohiro Sakamoto Kosuke Yamaguchi Masahiro Kodani Shinya Kawase Yoshihisa Umekit Source Type: research

A Recent Review On 3d-Printing: Scope And Challenges With Special Focus On Pharmaceutical Field
CONCLUSION: The authors hope that this article will give a valuable boost to energize future researcher working in the pharmaceutical field. Due to the novelty and particular highlights, 3D printing has the inborn ability to settle numerous formulation and medication conveyance challenges, which are often connected with poorly aqueous solubility. It has many unmet regulatory challenges that need to be addressed.PMID:35747955 | DOI:10.2174/1381612828666220623091629 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - June 24, 2022 Category: Drugs & Pharmacology Authors: Shubham Singh Mohit Kumar Abd Almonem Doolaanea Uttam K Mandal Source Type: research

Fanconi syndrome in an elderly patient with membranous nephropathy during treatment with the immunosuppressant mizoribine
We report on an 80-year-old man diagnosed with Fanconi syndrome induced by mizoribine after 4  weeks of administration to treat membranous nephropathy. Mizoribine is an oral immunosuppressant that inhibits inosine monophosphate dehydrogenase and is widely used in Japan for the treatment of autoimmune diseases and nephrotic syndrome, as well as after renal transplantation. Acquired Fanconi s yndrome is often caused by drugs (antibacterial, antiviral, anticancer, and anticonvulsant drugs) and is sometimes caused by autoimmune diseases, monoclonal light chain-associated diseases, or heavy metal poisoning. In our patient, hyp...
Source: CEN Case Reports - June 24, 2022 Category: Urology & Nephrology Source Type: research

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of < em > BCL2 < /em > and < em > BCLXL < /em > following glucocorticoid treatment
Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2021.280405. Online ahead of print.ABSTRACTPhysiologic and pathogenic IL7-receptor (IL7R) induced signaling provokes glucocorticoid resistance in a subset of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients. Activation of downstream STAT5 has been suggested to cause steroid resistance through upregulation of anti-apoptotic BCL2, one of its downstream target genes. Here, we demonstrate that isolated STAT5 signaling in various T-ALL cell models is insufficient to raise cellular steroid resistance despite upregulation of BCL2 and BCL-XL. Upregulation of anti-apop...
Source: Haematologica - June 23, 2022 Category: Hematology Authors: Jordy C G Van der Zwet Valentina Cordo' Jessica G C A M Buijs-Gladdines Rico Hagelaar Willem K Smits Eric Vroegindeweij Laura T M Graus Vera Poort Marloes Nulle Rob Pieters Jules P P Meijerink Source Type: research

STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of < em > BCL2 < /em > and < em > BCLXL < /em > following glucocorticoid treatment
Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2021.280405. Online ahead of print.ABSTRACTPhysiologic and pathogenic IL7-receptor (IL7R) induced signaling provokes glucocorticoid resistance in a subset of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients. Activation of downstream STAT5 has been suggested to cause steroid resistance through upregulation of anti-apoptotic BCL2, one of its downstream target genes. Here, we demonstrate that isolated STAT5 signaling in various T-ALL cell models is insufficient to raise cellular steroid resistance despite upregulation of BCL2 and BCL-XL. Upregulation of anti-apop...
Source: Haematologica - June 23, 2022 Category: Hematology Authors: Jordy C G Van der Zwet Valentina Cordo' Jessica G C A M Buijs-Gladdines Rico Hagelaar Willem K Smits Eric Vroegindeweij Laura T M Graus Vera Poort Marloes Nulle Rob Pieters Jules P P Meijerink Source Type: research

The Case | Inflammatory polyarthritis in a kidney transplant recipient
A 52-year-old man underwent live donor kidney transplantation for end-stage kidney disease in 2001 (20 years post-transplant). His maintenance immunosuppressive therapy was tacrolimus, azathioprine, and prednisolone. He had chronic allograft dysfunction (serum creatinine level of 3 mg/dl). Twenty years post-transplant, he presented with pain and swelling of small joints of the hand of 4 months duration, along with early morning stiffness. On examination, he had swelling and tenderness of bilateral wrist, metacarpophalangeal joints, and proximal interphalangeal joints. (Source: Kidney International)
Source: Kidney International - June 20, 2022 Category: Urology & Nephrology Authors: Karthikeyan Manoharan, Priyansh Gupta, Hitaishi Mehta, Ritambhra Nada, Aravind Sekar, Ashwani Kumar, Aman Sharma, Manish Rathi, Harbir Singh Kohli, Keshavamurthy Vinay, Raja Ramachandran Tags: Make Your Diagnosis Source Type: research

Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : Study protocol for a  three-armed, randomized, triple-blind, multicenter trial (HODOKORT)
DISCUSSION: There is an unmet medical need for an effective medical therapy of ISSHL. Although sensorineural hearing impairment can be partially compensated by hearing aids or cochlear implants (CI), generic hearing is better than using hearing aids or CIs. Since adverse effects of a short course of high-dose systemic corticosteroids have not been documented with good evidence, the trial will improve knowledge on possible side effects in the different treatment arms with a focus on hyperglycemia and hypertension.TRIAL REGISTRATION: EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) Nr. 2015-00260...
Source: HNO - June 20, 2022 Category: ENT & OMF Authors: Stefan K Plontke Matthias Girndt Christoph Meisner Iris B öselt Beatrice Ludwig-Kraus Michael Richter Torsten Rahne Source Type: research

Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis
The objectives of the study were to analyze the efficacy of different therapeutic options for DM-ILD to identify the optimal therapy. A total of 60 patients had received intravenous 1.0-2.0 mg/ kg/day prednisolone for DM-ILD. In severe conditions, patients had received oral 1 to 3 mg/day tacrolimus (TAC), 500 mg/ m2/month cyclophosphamide (CY), and/or 1 g/ day methylprednisolone pulse (TI cohort, n = 24). In severe conditions, patients had received 1 g/day methylprednisolone pulse and 2-3 mg/ kg/day cyclosporine A (CsA) and/or 500 mg/ m2/month CY (existing historical treatment; CT cohort, n = 36). Patients of the TI cohort...
Source: Herpes - June 17, 2022 Category: Infectious Diseases Authors: Lian Li Mu Li Yingchun Li Kang Wang Shengqian Xu Source Type: research

Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis
The objectives of the study were to analyze the efficacy of different therapeutic options for DM-ILD to identify the optimal therapy. A total of 60 patients had received intravenous 1.0-2.0 mg/ kg/day prednisolone for DM-ILD. In severe conditions, patients had received oral 1 to 3 mg/day tacrolimus (TAC), 500 mg/ m2/month cyclophosphamide (CY), and/or 1 g/ day methylprednisolone pulse (TI cohort, n = 24). In severe conditions, patients had received 1 g/day methylprednisolone pulse and 2-3 mg/ kg/day cyclosporine A (CsA) and/or 500 mg/ m2/month CY (existing historical treatment; CT cohort, n = 36). Patients of the TI cohort...
Source: Herpes - June 17, 2022 Category: Infectious Diseases Authors: Lian Li Mu Li Yingchun Li Kang Wang Shengqian Xu Source Type: research

A Case of Sterile Corneal Stromal Infiltration with Hypotonic Maculopathy Under Brimonidine Treatment
CONCLUSION: Our case report suggests monitoring patients under brimonidine for sterile corneal infiltration.PMID:35708458 | DOI:10.1080/09273948.2022.2087687 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - June 16, 2022 Category: Allergy & Immunology Authors: Lourdes Vidal Oliver Andrea D íaz Barrón Ana L ópez Montero Irene Gil-Hern ández Antonio Miguel Duch Samper Source Type: research